TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10872536

Group type: EXPERIMENTAL
Intervention: Insulin analogue insulin aspart (IAsp) administered 15 min after the meal (IAsp(+15min))
Number of subjects: 20

Group type: COMPARATOR
Intervention: Soluble human insulin (HI) administered immediately before the meal (HI(0min))
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Insulin analogue insulin aspart (IAsp) administered immediately before the meal (IAsp(0min))
Number of subjects: 20

Group type: COMPARATOR
Intervention: Soluble human insulin (HI) administered 15 min before the meal (HI(-15min))
Number of subjects: 20
Study: 9117225

Group type: EXPERIMENTAL
Intervention: Gonadotrophin-releasing hormone agonist triptorelin for 3 months before radical prostatectomy (group I)
Number of subjects: 38

Group type: COMPARATOR
Intervention: No prior therapy (group II)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 38
Study: 8399863

Group type: EXPERIMENTAL
Intervention: Clindamycin/primaquine
Number of subjects: 65

Group type: COMPARATOR
Intervention: TMP-SMZ
Number of subjects: 65
Study: 3947710

Group type: EXPERIMENTAL
Intervention: Naltrexone (300 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 3244786

Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy (ECT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Anesthetic therapy with isoflurane
Number of subjects: 0
Study: 30501974

Group type: EXPERIMENTAL
Intervention: 1·1 GBq radioactive iodine ablation
Number of subjects: 438

Group type: COMPARATOR
Intervention: 3·7 GBq radioactive iodine ablation
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: Preparation with rhTSH
Number of subjects: 438

Group type: COMPARATOR
Intervention: Preparation with thyroid hormone withdrawal
Number of subjects: 438
Study: 29087285

Group type: EXPERIMENTAL
Intervention: Ascorbic acid (2 grams 24 hours and 2 hours preoperatively, 1 gram twice daily for five days post-surgery)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no ascorbic acid)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Ascorbic acid group
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study: 26040627

Group type: EXPERIMENTAL
Intervention: Aspergillus niger prolyl endoprotease (AN-PEP) with low calorie meal
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Aspergillus niger prolyl endoprotease (AN-PEP) with high calorie meal
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo with low calorie meal
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo with high calorie meal
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Aspergillus niger prolyl endoprotease (AN-PEP) with low calorie meal (duodenum)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Aspergillus niger prolyl endoprotease (AN-PEP) with high calorie meal (duodenum)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo with low calorie meal (duodenum)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo with high calorie meal (duodenum)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Aspergillus niger prolyl endoprotease (AN-PEP) with low calorie meal (absolute AUC)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Aspergillus niger prolyl endoprotease (AN-PEP) with high calorie meal (absolute AUC)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo with low calorie meal (absolute AUC)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo with high calorie meal (absolute AUC)
Number of subjects: 12
Study: 22974480

Group type: EXPERIMENTAL
Intervention: Shenghuan disposable device (Yan's method)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Shenghuan disposable device (Peng's method)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Conventional scalpel/suture technique
Number of subjects: 120
Study: 21656472

Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide injection
Number of subjects: 70

Group type: COMPARATOR
Intervention: Sterile water injection (Control)
Number of subjects: 70
Study: 19351224

Group type: EXPERIMENTAL
Intervention: Rasburicase (4.5 mg in 100-cc physiological solution)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo (physiological solution)
Number of subjects: 38
Study: 16761193

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa (300 microg bolus)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control (no additional medication)
Number of subjects: 22
Study: 14993085

Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 3050

Group type: EXPERIMENTAL
Intervention: Autodialer (automated telephone or mail reminder recall)
Number of subjects: 3050

Group type: EXPERIMENTAL
Intervention: Outreach (in‐person telephone, mail, or home visit recall)
Number of subjects: 3050

Group type: EXPERIMENTAL
Intervention: Combination (autodialer with outreach backup)
Number of subjects: 3050
Study: 11564911

Group type: EXPERIMENTAL
Intervention: Alcohol (0.7 g/kg body mass)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Alcohol-free solution
Number of subjects: 11
Study: 9426358

Group type: EXPERIMENTAL
Intervention: Pure carbohydrate meal
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Pure fat meal
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Mixed meal (carbohydrate, fat, and protein)
Number of subjects: 16
Study: 8500311

Group type: EXPERIMENTAL
Intervention: Smoking intervention and use of an inhaled bronchodilator
Number of subjects: 6000

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 6000
Study: 3326025

Group type: EXPERIMENTAL
Intervention: Omnipaque (iohexol)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Ultravist-300 (iopromide)
Number of subjects: 50
Study: 29908290

Group type: EXPERIMENTAL
Intervention: 30-gauge syringe needle irrigation (SNI)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: EDDY (sonic-powered irrigation system)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Positive control (no irrigation)
Number of subjects: 38
Study: 27051670

Group type: EXPERIMENTAL
Intervention: Vitamin B-6 50 mg/d for 12 weeks
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 23659494

Group type: EXPERIMENTAL
Intervention: Vitamin C (1 g/day) + Vitamin E (400 IU/day)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 22970896

Group type: EXPERIMENTAL
Intervention: Low frequency lithotripsy (60 pulses per min)
Number of subjects: 154

Group type: COMPARATOR
Intervention: High frequency lithotripsy (80 pulses per min)
Number of subjects: 154
Study: 20483811

Group type: EXPERIMENTAL
Intervention: Lanarkshire Oximetry Index (LOI) cut-off value <0.9
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Lanarkshire Oximetry Index (LOI) cut-off value <0.8
Number of subjects: 161

Group type: COMPARATOR
Intervention: Ankle‐Brachial Index (ABI)
Number of subjects: 161
Study: 18825652

Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Carbamazepine (CBZ)
Number of subjects: 0
Study: 16649826

Group type: EXPERIMENTAL
Intervention: Dermatologic Precautions (DP)
Number of subjects: 1175

Group type: COMPARATOR
Intervention: Usual Care Precautions (UCP)
Number of subjects: 1175

Group type: EXPERIMENTAL
Intervention: Lamotrigine (added to existing therapy)
Number of subjects: 1175
Study: 14663655

Group type: EXPERIMENTAL
Intervention: Rivastigmine or donepezil (acetylcholinesterase inhibitors)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 35
Study: 11783240

Group type: EXPERIMENTAL
Intervention: Qinggan Jiedu Sanjie Decoction
Number of subjects: 110

Group type: COMPARATOR
Intervention: Routine western medicine
Number of subjects: 110
Study: 8546117

Group type: EXPERIMENTAL
Intervention: Hormone therapy (oral and transdermal)
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Oral estrogen therapy
Number of subjects: 277

Group type: COMPARATOR
Intervention: No hormone therapy
Number of subjects: 277

Group type: COMPARATOR
Intervention: Upper body fat distribution
Number of subjects: 277
Study: 1930358

Group type: EXPERIMENTAL
Intervention: Citrulline malate (Stimol, CAS 54940‐97‐5)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7173304

Group type: EXPERIMENTAL
Intervention: slow-release indomethacin tablet
Number of subjects: 30

Group type: COMPARATOR
Intervention: conventional indomethacin capsule
Number of subjects: 30
Study: 29862649

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII) after 6 months
Number of subjects: 259

Group type: COMPARATOR
Intervention: Multiple daily injections (MDI) of insulin
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Responders to CSII therapy
Number of subjects: 259
Study: 27176493

Group type: EXPERIMENTAL
Intervention: Change Ahead group (6-session cognitive-behavioral program)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Educational brochure control condition
Number of subjects: 59
Study: 25440307

Group type: EXPERIMENTAL
Intervention: Child- and family-focused cognitive-behavioral therapy (CFF-CBT)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Psychotherapy as usual (control)
Number of subjects: 69
Study: 23224387

Group type: EXPERIMENTAL
Intervention: Glenoid positioning system group (patient-specific instrumentation with 3D CT scan planning)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Standard surgical group (conventional CT scan and surgical technique)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Glenoid positioning system group (for patients with retroversion > 16°)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Standard surgical group (for patients with retroversion > 16°)
Number of subjects: 31
Study: 19749006

Group type: EXPERIMENTAL
Intervention: Noninvasive mechanical ventilation (NIMV)
Number of subjects: 50

Group type: COMPARATOR
Intervention: High-flow oxygen mask (Control)
Number of subjects: 50
Study: 18507735

Group type: EXPERIMENTAL
Intervention: Dextromethorphan (DEX) at 480 mg/day for 5 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Dextromethorphan (DEX)
Number of subjects: 40
Study: 15638900

Group type: EXPERIMENTAL
Intervention: Solifenacin 5 mg once daily
Number of subjects: 3621

Group type: EXPERIMENTAL
Intervention: Solifenacin 10 mg once daily
Number of subjects: 3621

Group type: EXPERIMENTAL
Intervention: Solifenacin (both doses pooled)
Number of subjects: 3621

Group type: EXPERIMENTAL
Intervention: Solifenacin (extension study)
Number of subjects: 3621

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3621
Study: 11856090

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg once daily, clarithromycin 250 mg twice daily, and metronidazole 500 mg twice daily (LCM group)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Lansoprazole 30 mg twice daily, clarithromycin 500 mg twice daily, and amoxicillin 1000 mg twice daily (LCA group)
Number of subjects: 134

Group type: COMPARATOR
Intervention: LCA group
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: LCM group
Number of subjects: 134
Study: 10208193

Group type: EXPERIMENTAL
Intervention: Combination of ipratropium bromide (42 microg qid) and albuterol sulfate (240 microg qid)
Number of subjects: 1067

Group type: COMPARATOR
Intervention: Ipratropium bromide (36 microg qid)
Number of subjects: 1067

Group type: COMPARATOR
Intervention: Albuterol base (180 microg qid)
Number of subjects: 1067
Study: 8581377

Group type: EXPERIMENTAL
Intervention: BIS‐1 F(ab')2 at doses of 1, 3, or 5 micrograms/kg body weight during concomitantly applied subcutaneous IL‐2 treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BIS‐1 F(ab')2 at doses of 3 and 5 micrograms/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BIS‐1 F(ab')2
Number of subjects: 0
Study: 2564912

Group type: EXPERIMENTAL
Intervention: 0.5% podofilox applied by patients to their own genital warts in up to four treatment cycles
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: 0.5% podofilox
Number of subjects: 109

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 109
Study: 1052

Group type: EXPERIMENTAL
Intervention: timepidium-bromide
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: hyoscine-N-butylbromide
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: prifinium-bromide
Number of subjects: 101

Group type: COMPARATOR
Intervention: placebo (physiological saline solution)
Number of subjects: 101
Study: 30753539

Group type: EXPERIMENTAL
Intervention: Integrated Vector Management (IVM) including community awareness, education, source reduction, larviciding, and mass trapping with autocidal gravid ovitraps (AGO)
Number of subjects: 61511
Study: 27283007

Group type: EXPERIMENTAL
Intervention: Segmental area of late gadolinium-enhancement (SEE)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Microvascular obstruction (not assessable in 25% of patients)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Feature tracking-derived circumferential strain (Ecc)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Markers of myocardial injury (MSI)
Number of subjects: 164
Study: 24837544

Group type: EXPERIMENTAL
Intervention: HI-FIVES group (skills training program)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Usual care (information about VA Caregiver Support Services Program)
Number of subjects: 240
Study: 22118824

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 2248

Group type: COMPARATOR
Intervention: No Warfarin (Control)
Number of subjects: 2248
Study: 20688020

Group type: EXPERIMENTAL
Intervention: Topical application of 3 ml of 0.5% bupivacaine for 5 minutes
Number of subjects: 46

Group type: COMPARATOR
Intervention: No local anaesthetic (control)
Number of subjects: 46
Study: 19067373

Group type: EXPERIMENTAL
Intervention: Miglustat
Number of subjects: 30

Group type: COMPARATOR
Intervention: No miglustat treatment (Control)
Number of subjects: 30
Study: 16190480

Group type: EXPERIMENTAL
Intervention: Fibrin sealant
Number of subjects: 494

Group type: COMPARATOR
Intervention: Nasal packing
Number of subjects: 494
Study: 12867383

Group type: EXPERIMENTAL
Intervention: Verteporfin therapy at a drug dose of 6 mg/m(2) body surface area and a light dose of 50 J/cm(2)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham treatment with placebo infusion and light exposure
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Verteporfin therapy
Number of subjects: 60
Study: 10344660

Group type: EXPERIMENTAL
Intervention: 750 mg of atovaquone (7 daily doses)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 250 mg of atovaquone (single dose)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 1824651

Group type: EXPERIMENTAL
Intervention: Doxazosin (mean dose at 3 years, 5.2 mg/day)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Atenolol (mean dose, 66.4 mg/day)
Number of subjects: 164
Study: 6346595

Group type: EXPERIMENTAL
Intervention: 30 mg/kg ALG administered daily for 10 days by intravenous infusion
Number of subjects: 173

Group type: COMPARATOR
Intervention: Placebo administered daily for 10 days by intravenous infusion
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: ALG
Number of subjects: 173

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Live donor grafts
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Least donor‐recipient histocompatibility mismatches
Number of subjects: 173
Study: 30944136

Group type: EXPERIMENTAL
Intervention: Off pump injectable pulmonary valve replacement
Number of subjects: 0

Group type: COMPARATOR
Intervention: On pump conventional pulmonary valve replacement
Number of subjects: 0
Study: 28464426

Group type: EXPERIMENTAL
Intervention: Perioperative behavioral/pelvic floor exercise intervention + MUS
Number of subjects: 0

Group type: COMPARATOR
Intervention: MUS alone
Number of subjects: 0
Study: 26847748

Group type: EXPERIMENTAL
Intervention: Cardiac surgery with cardiopulmonary bypass
Number of subjects: 95
Study: 24451146

Group type: EXPERIMENTAL
Intervention: Tamoxifen +/− octreotide
Number of subjects: 667
Study: 23241359

Group type: EXPERIMENTAL
Intervention: Gum Arabic (GA) 30 gm/day for 6 weeks
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (pectin 1 gm/day for 6 weeks)
Number of subjects: 120
Study: 20002638

Group type: EXPERIMENTAL
Intervention: Prevelle SILK (hyaluronic acid with lidocaine)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Captique (hyaluronic acid without lidocaine)
Number of subjects: 45
Study: 17547890

Group type: EXPERIMENTAL
Intervention: Low‐cholesterol low‐saturated fat diet (n = 141)
Number of subjects: 290

Group type: COMPARATOR
Intervention: Usual diet (control subjects; n = 149)
Number of subjects: 290
Study: 16295781

Group type: EXPERIMENTAL
Intervention: CY 4 g/m2 plus lenograstim (arm A)
Number of subjects: 27

Group type: COMPARATOR
Intervention: CY 1.5 g/m2 plus lenograstim (arm B)
Number of subjects: 27
Study: 12450894

Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation (specifics not provided)
Number of subjects: 2069

Group type: EXPERIMENTAL
Intervention: Coffee and alcohol consumption (decrease recommended for women)
Number of subjects: 2069

Group type: EXPERIMENTAL
Intervention: Physical activity, dietary fiber, and folate intake (increase recommended for men)
Number of subjects: 2069
Study: 9783933

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 284
Study: 7746341

Group type: EXPERIMENTAL
Intervention: Neural transplantation
Number of subjects: 0
Study: 1827344

Group type: EXPERIMENTAL
Intervention: 0.1% w/w CD 271 alcoholic gel
Number of subjects: 72

Group type: COMPARATOR
Intervention: 0.025% w/w tretinoin gel
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 0.03% w/w CD 271 alcoholic gel
Number of subjects: 72
Study: 7313587

Group type: EXPERIMENTAL
Intervention: Metronidazole 2.0 g on 2 consecutive days
Number of subjects: 50

Group type: COMPARATOR
Intervention: Tinidazole 2.0 g as a single dose
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Metronidazole 200 mg 3 times daily for 1 week
Number of subjects: 50
Study: 30870364

Group type: EXPERIMENTAL
Intervention: Intratympanic methylprednisolone (62.5 mg/mL)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Intratympanic gentamicin (40 mg/mL)
Number of subjects: 46
Study: 28403362

Group type: EXPERIMENTAL
Intervention: 0.8% (w/v) hyaluronic acid (HA)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 40
Study: 26215224

Group type: EXPERIMENTAL
Intervention: Conventional exercises
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Multisensory exercises
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Dual-task exercises
Number of subjects: 44
Study: 22892021

Group type: EXPERIMENTAL
Intervention: Vibration perception threshold (VPT) measured using a neurothesiometer
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: 10-g Semmes-Weinstein monofilament (SWF) test
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Both tests (VPT and SWF)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: VPT
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: SWF
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Agreement between VPT and SWF
Number of subjects: 400
Study: 23330199

Group type: EXPERIMENTAL
Intervention: Encephabol (suspension form, daily dosage 200‐250 mg, or 12‐15 mg/kg) for 2 months
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no medication)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Encephabol
Number of subjects: 40
Study: 19196080

Group type: COMPARATOR
Intervention: High-intensity exercise training (HI)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Moderate-intensity exercise training (MI)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 18
Study: 17300287

Group type: EXPERIMENTAL
Intervention: Itopride 100 mg t.i.d.
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Itopride 200 mg t.i.d.
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo t.i.d.
Number of subjects: 46
Study: 15362772

Group type: EXPERIMENTAL
Intervention: TACE plus thymosin alpha1 postoperatively (Group A)
Number of subjects: 57

Group type: COMPARATOR
Intervention: TACE postoperatively (Group B)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Hepatectomy only (Group C)
Number of subjects: 57
Study: 11589257

Group type: EXPERIMENTAL
Intervention: parecoxib sodium (10 mg BID)
Number of subjects: 17

Group type: COMPARATOR
Intervention: ketorolac (15 mg QID)
Number of subjects: 17

Group type: COMPARATOR
Intervention: naproxen (500 mg BID)
Number of subjects: 17

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 17
Study: 9433424

Group type: EXPERIMENTAL
Intervention: Phenobarbital (1.5 mg/kg daily for 2 weeks; maintenance dose 3.0 mg/kg daily)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Phenytoin (2.5 mg/kg daily then 5.0 mg/kg daily)
Number of subjects: 94
Study: 7986761

Group type: EXPERIMENTAL
Intervention: Telephone contact (intervention arm)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual care (control arm)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Analysis by intention to treat (intervention)
Number of subjects: 100
Study: 2185154

Group type: EXPERIMENTAL
Intervention: Cefamandole
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 40
Study: 453504

Group type: EXPERIMENTAL
Intervention: Nitrous oxide at 66% for the first 3 minutes
Number of subjects: 2

Group type: COMPARATOR
Intervention: Anaesthetic based on oxygen 66%, nitrous oxide 33% and halothane 0.4%
Number of subjects: 2
Study: 30593457

Group type: EXPERIMENTAL
Intervention: Intravesical BCG therapy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Intravesical BCG ± intradermal HS-410 therapy
Number of subjects: 50
Study: 28634659

Group type: EXPERIMENTAL
Intervention: Moor bath (42 °C, 20 min) followed by a resting period (20 min)
Number of subjects: 78
Study: 25468282

Group type: EXPERIMENTAL
Intervention: Acupressure (15 min, three times a week for four weeks)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control group (usual care with routine hemodialysis treatment)
Number of subjects: 108
Study: 22833377

Group type: EXPERIMENTAL
Intervention: Iguratimod (25 mg/day for the first 4 weeks, then 50 mg/day for the subsequent 20 weeks) with MTX (6 or 8 mg/week)
Number of subjects: 253

Group type: COMPARATOR
Intervention: Placebo with MTX (6 or 8 mg/week)
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Iguratimod with MTX
Number of subjects: 253